Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.
Fowler JS, Logan J, Volkow ND, Shumay E, McCall-Perez F, Jayne M, Wang GJ, Alexoff DL, Apelskog-Torres K, Hubbard B, Carter P, King P, Fahn S, Gilmor M, Telang F, Shea C, Xu Y, Muench L.
Fowler JS, et al. Among authors: volkow nd.
Neuropsychopharmacology. 2015 Feb;40(3):650-7. doi: 10.1038/npp.2014.214. Epub 2014 Sep 24.
Neuropsychopharmacology. 2015.
PMID: 25249059
Free PMC article.
Clinical Trial.